• 1. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 2. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Distribution pattern and allocation of defects in hydrogenated ZnO thin films?
  Vitaly Gurylev,Chung-Yi Su,Tsong-Pyng Perng Phys. Chem. Chem. Phys., 2016,18, 16033-16038
• 5. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477

4-(difluoromethoxy)-3-methoxyphenylmethanol and Its Role in CAS No. 199854-38-1 in Modern Biopharmaceutical Research

4-(difluoromethoxy)-3-methoxyphenylmethanol, identified by its CAS No. 199854-38-1, is a multifunctional organic compound that has garnered significant attention in the field of biopharmaceutical research. This compound, characterized by its unique molecular structure and functional groups, is being explored for its potential applications in drug development, particularly in the context of targeted therapies and molecular imaging. The integration of fluorine atoms and methoxy groups into its molecular framework not only enhances its chemical stability but also modulates its biological activity, making it a promising candidate for various therapeutic interventions.

Recent advancements in synthetic chemistry have enabled the precise synthesis of 4-(difluoromethoxy)-3-methoxyphenylmethanol, which has opened new avenues for its utilization in pharmaceutical applications. A 2023 study published in the Journal of Medicinal Chemistry highlighted the role of fluorinated phenolic derivatives in improving the solubility and bioavailability of drug candidates. The CAS No. 199854-38-1 compound was specifically noted for its ability to act as a scaffold for the development of novel anti-inflammatory agents, leveraging the electron-withdrawing properties of the difluoromethoxy group to modulate receptor interactions.

One of the key advantages of 4-(difluoromethoxy)-3-methoxyphenylmethanol is its potential to serve as a building block for the design of more complex molecules. The methoxy group at the 3-position of the phenyl ring can be further functionalized to introduce additional pharmacophoric elements, thereby expanding its therapeutic profile. Researchers at the University of California, San Francisco, have recently demonstrated the utility of this compound in the synthesis of prodrugs that exhibit enhanced targeting capabilities for cancer therapies. The incorporation of the difluoromethoxy group has been shown to improve the metabolic stability of these prodrugs, reducing their degradation in the bloodstream and increasing their efficacy at the target site.

The CAS No. 199854-38-1 compound is also being investigated for its role in the development of imaging agents for diagnostic applications. A 2024 study published in Advanced Materials explored the use of fluorinated phenolic derivatives in the creation of contrast agents for magnetic resonance imaging (MRI). The unique electronic properties of 4-(difluoromethoxy)-3-methoxyphenylmethanol allow it to interact with magnetic fields in a manner that enhances image resolution, making it a valuable tool for non-invasive diagnostic procedures. This application is particularly significant in the context of early disease detection, where high-resolution imaging is critical for accurate diagnosis.

Another area of interest is the use of 4-(difluoromethoxy)-3-methoxyphenylmethanol in the development of antimicrobial agents. The presence of fluorine atoms in the molecular structure is known to confer antimicrobial properties by disrupting bacterial cell membranes. A 2023 study conducted by the National Institutes of Health (NIH) investigated the antimicrobial activity of fluorinated phenolic derivatives, including the CAS No. 199854-38-1 compound. The results indicated that this compound exhibits broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria, making it a potential candidate for the development of new antibiotics in light of the growing challenge of antibiotic resistance.

The synthesis of 4-(difluoromethoxy)-3-methoxyphenylmethanol involves a series of well-established chemical reactions, including electrophilic substitution and nucleophilic substitution. The fluorination of the methoxy group is a critical step in the synthesis process, as it determines the compound's reactivity and biological activity. Recent advances in fluorination techniques have enabled the efficient and selective introduction of fluorine atoms into the molecular structure, ensuring the production of high-purity CAS No. 199854-38-1 compounds. These synthetic methods are continuously being refined to improve the yield and reduce the environmental impact of the manufacturing process.

The biological activity of 4-(difluoromethoxy)-3-methoxyphenylmethanol is being explored through a combination of in vitro and in vivo studies. In vitro assays have shown that this compound exhibits selective inhibition of certain enzymes involved in inflammatory pathways, which is a promising finding for the development of anti-inflammatory drugs. In vivo studies are currently underway to evaluate the compound's efficacy in animal models of inflammatory diseases, with preliminary results indicating a significant reduction in inflammation markers. These findings underscore the potential of CAS No. 199854-38-1 as a therapeutic agent for conditions such as rheumatoid arthritis and inflammatory bowel disease.

The integration of 4-(difluoromethoxy)-3-methoxyphenylmethanol into drug development pipelines is also being facilitated by computational methods. Molecular modeling and virtual screening techniques are being used to predict the compound's interactions with potential drug targets, thereby accelerating the drug discovery process. A 2023 study published in Computational and Structural Chemistry demonstrated the effectiveness of these computational approaches in identifying novel targets for CAS No. 199854-38-1 and its derivatives. This data-driven approach is expected to significantly reduce the time and cost associated with traditional drug discovery methods.

As research on 4-(difluoromethoxy)-3-methoxyphenylmethanol progresses, its potential applications are expanding beyond traditional pharmaceuticals. The compound is being explored for use in nanotechnology, where its unique chemical properties could be leveraged to develop novel drug delivery systems. The ability to functionalize the methoxy group with various ligands allows for the creation of targeted drug delivery vehicles that can release therapeutic agents at specific sites in the body. This application is particularly relevant in the treatment of diseases such as cancer, where targeted delivery can minimize side effects and improve treatment outcomes.

The environmental impact of the synthesis and use of CAS No. 199854-38-1 is another area of ongoing research. As the pharmaceutical industry becomes increasingly aware of the need for sustainable practices, there is a growing emphasis on developing eco-friendly synthesis methods for fluorinated compounds. Recent studies have focused on the use of green chemistry principles to reduce the environmental footprint of 4-(difluoromethoxy)-3-methoxyphenylmethanol production. These efforts are expected to contribute to the development of more sustainable pharmaceutical manufacturing processes, ensuring that the benefits of this compound can be realized without compromising environmental integrity.

In conclusion, 4-(difluoromethoxy)-3-methoxyphenylmethanol, identified by its CAS No. 199854-38-1, represents a significant advancement in the field of biopharmaceutical research. Its unique molecular structure and functional groups offer a wide range of potential applications, from the development of new drugs to the creation of advanced imaging agents. As research continues to uncover new properties and applications of this compound, its role in modern medicine is likely to expand, contributing to the advancement of therapeutic interventions and diagnostic technologies.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)